Over the last decade hypothesis-driven candidate gene studies have come to dominate psychiatric genetics research. However, despite this proliferation, to date few genetic effects have been successfully identified and independently replicated. 1 One of the factors limiting the success of this approach is likely to be fine-scale variation in linkage disequilibrium (LD) across the gene of interest. Incomplete correlation between the genotyped marker and causative variant will reduce the available statistical power and limit the capacity for detecting small effects. 2 In order to circumvent these difficulties, potential candidate genes can be prioritised in terms of variant functionality, thereby increasing the probability that the genotyped marker is the disease-causing variant. With the advent of large-scale sequencing projects such as HAPMAP, 3 it is now possible to select variants for analysis from large publicly available databases on the basis of their predicted consequences and the expression patterns of their host gene. Here we briefly describe an application of this method, and report the identification of a single gene that associates with self-report lifetime major depression (MD) history (defined according to DSM-IV criteria 4 ). We generated a composite list of single nucleotide polymorphisms (SNPs) derived from NCBI and Ensembl, and annotated as causing de novo stop or splice sites in either one or both databases. These SNPs were then parsed for evidence of validation, and the resulting variants (premature termination n = 501, splice variant n = 186) subject to a literature search for evidence of neural expression and/or involvement in a neurobehavioural trait. A total of 25 potential candidates were identified. These SNPs were genotyped on a Sequenom platform in a large sample of singletons (n = 918) selected from a southwest England community cohort (n = 88,142) on the basis of extremity of Neuroticism score (a continuous phenotype which is estimated to share around 55% of its genetic liability with MD 5 ). Details of sample selection and data collection are provided elsewhere. 6, 7 Power calculations (Willis-Owen et al. 6 ) indicated that 700 individuals would provide sufficient power to detect a genetic effect accounting for just 0.75% of variance across a range of allele frequencies (from 0.1 to 0.5). Genotypes were therefore obtained on an average of 805 individuals. Of the 25 markers genotyped, six were found to be nonpolymorphic in our sample and five failed to produce satisfactory amplification. The remaining 14 markers were examined for association with self-report lifetime MD through a w 2 contingency table analysis (alpha = 0.05). Only one marker (rs12520799) yielded a significant association (w 2 = 11.55, P = 0.003). This association was obtained across 882 individuals (62.5% female) with an average age of 41 years, 4 months.
A false discovery rate (calculated according to the method described in Benjamini and Hochberg 8 ) indicated that there is a 95% chance that this genotype-phenotype association is genuine (i.e. not a type I error). Consistent with these data, and the use of an extremes selection design, the allele frequencies for marker rs12520799 were found to depart significantly from Hardy-Weinberg equilibrium due to a homozygote excess and paucity of heterozygotes (w 2 = 722 1 , P < 0.05, see Table 1 ). Since only a
Letters to the Editor small number of heterozygotes were present in the genotyped sample (n = 18) we excluded these individuals from further analysis. Examination of relative MD frequencies in each homozygous genotype group showed that the less prevalent T allele (the termination allele) was associated with an increased prevalence of MD (65% relative to 48%) in both sexes. Likewise, Neuroticism score (arcsine-transformed and age-regressed) was also found to be elevated in TT homozygotes, although this difference did not reach statistical significance (f = 3.0 1 , P = 0.08). Marker rs12520799 is located in dendritic cell nuclear protein 1 (DCNP1) on chromosome 5 where it yields a premature termination of translation at codon number 117. DCNP1 is expressed in both human brain and skeletal muscle, where it localises to the perinucleus of mature, and to a lesser extent immature dendritic cells. 9 These cells moderate antigen-specific T-cell immunity 10 in a maturationdependent manner. 11, 12 No information is available at present regarding structure-specific expression patterns of DCNP1 within the brain. DCNP1 is a novel candidate gene for MD that requires independent replication in a large sample. However, the observed effect of this premature termination variant is small compared with the large displacements typically associated with premature termination mutations in mendelian disease traits. Consequently, it remains unclear whether the approach described here is likely to represent a productive strategy for complex trait dissection.
Recently a study in Molecular Psychiatry reported an association between neuroanatomical endophenotype and val66met brain-derived neurotrophic factor (BDNF) polymorphism. The val/val homozygotes had larger hippocampal volumes than the val/met heterozygotes and such relationship was stronger in schizophrenic patients than in control subjects. 1 We previously observed an association between this polymorphism and cognitive endophenotype (performance on the Wisconsin Card Sorting Test -WCST) in bipolar patients, where the val/val homozygotes scored better on this test than the val/met heterozygotes. 2 We extended this research to a greater number of bipolar patients as well as to schizophrenic and control subjects and found that this association is specific to bipolar illness and does not occur either in schizophrenic patients or in controls.
The analysis was performed on 111 patients with bipolar mood disorder (37 male, 74 female), aged 18-72 (mean 43) years, with the mean onset of illness 31712 years, and on 129 schizophrenic patients (66 male, 63 female), aged 18-65 (mean 27) years, with the mean onset of illness 2376 years. All patients were hospitalized at inpatient clinic, Department of Adult Psychiatry, Poznan University of Medical Sciences. In all, 92 healthy control subjects were also studied (34 male, 58 female) aged 19-58 (mean 31) 
